Ainos Inc

Ainos, Inc. is a healthcare company engaged in the discovery and development of pharmaceutical and biotech products. It operates through the following divisions: Pharmaceutical, Medical, and Consumer. The company was founded in June 1984 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. Its medtech solutions include COVID-19 Antigen Rapid Test Kit, VOC POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha, and Synthetic RNA. The company was founded in June 1984 and is headquartered in San Diego, CA.

Subsequent Phase Involves Completion of Chemistry, Manufacturing, and Controls (CMC) Information Ainos Intends to Submit Investigational New Drug Applications to the U.S. FDA for Multiple Candidates During the First Half of 2024 Candidates include HIV Oral Warts Orphan Drug, Sjogren's Syndrome, the Common Cold, and COVID-19 SAN DIEGO, CA / ACCESSWIRE / November 28, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that its contract manufacturer, Swiss Pharmaceutical Co., Ltd. (Taiwan) ("Swiss Pharma"), has completed manufacturing of a Good Manufacturing Practice ("GMP") Clinical Batch of the Company's VELDONA® investigational new drugs.

Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical

Data partially fulfills the safety and efficacy hypotheses of one pilot and two Phase II clinical studies Ainos aims to pursue a pre-IND meeting with the U.S. FDA ahead of a planned Phase III study SAN DIEGO, CA / ACCESSWIRE / November 21, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that positive top-line data has been reported from three clinical studies for its VELDONA® low-dose oral interferon formulation as a potential treatment for oral warts in HIV-seropositive patients. The positive results partially fulfill the hypotheses of the three studies in establishing a safe daily dose, and demonstrate the formulation's superior efficacy compared to a placebo in relieving oral warts in HIV-seropositive individuals.

Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Product Cycle Transition Approaches its Final Stages New Product Line Expected to Gain Momentum in the Fourth Quarter SAN DIEGO, CA / ACCESSWIRE / November 9, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, VELDONA® low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the third quarter ended September 30, 2023. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "During the third quarter of 2023, we took key steps towards establishing new revenue streams.

Ainos Reports Third Quarter 2023 Financial Results

Ainos and SIDSCO will cooperate to accelerate the development of new animal drugs based on Ainos' VELDONA® low-dose oral interferon Upcoming clinical study will investigate VELDONA®'s safe use and efficacy for the treatment of feline chronic gingivostomatitis (FCGS) via oral mucosal administration SAN DIEGO, CA / ACCESSWIRE / November 6, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it had signed a Memorandum of Understanding ("MoU") with SIDSCO Biomedical Co., Ltd. ("SIDSCO").

Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA

Proceeds to fund company's clinical trials, commercial product launch, and working capital Initial conversion price set at $1.50 per share SAN DIEGO, CA / ACCESSWIRE / September 25, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, announced today that it has entered into a securities purchase agreement with Lind Global Fund II LP, an investment fund managed by The Lind Partners, a New York based institutional fund manager (together the "Investor") to issue and sell the initial $3 million tranche of a total anticipated $10 million private placement with $2 million funded at closing and $1 million to be funded subject to shareholder approval, effective registration statement and conditions specified in the agreement. The investment is in the form of a Senior Secured Convertible Promissory Note (the "Note").

Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement

Boston, Massachusetts--(Newsfile Corp. - September 19, 2023) - The U.S. Food and Drug Administration (FDA) has granted Ainos' (NASDAQ: AIMD) VELDONA Orphan Drug Designation (ODD) for the treatment of oral warts in HIV-seropositive patients. VELDONA is Very Low-Dose Oral Interferon Alpha, Ainos' proprietary oral lozenge formulation of Interferon alpha (IFN-) that has been extensively tested in preclinical and 68 human clinical studies, including three Phase 1, 63 Phase 2, and three Phase 3 studies, several which have been conducted in the U.S. To view the full announcement, including downloadable images, bios, and more, click here.

With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients

VELDONA® positioned as a potential treatment option for over 24,000 HIV-seropositive Americans SAN DIEGO, CA / ACCESSWIRE / September 18, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, announced today that the United States Food and Drug Administration (the "U.S. FDA") granted Orphan Drug Designation ("ODD") for the Company's VELDONA® low-dose oral interferon formulation as a potential treatment for oral warts in HIV-seropositive patients. Ainos plans to pursue a pre-IND meeting with the U.S. FDA in advance of planned Phase III clinical studies for the drug candidate.

Ainos' VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients

First Batch of 300,000 Units to be Fully Delivered in October Ainos Has Expanded Distribution in Multiple Channels and Plans to Scale Up Capacity for Expected Strong Demand SAN DIEGO, CA / ACCESSWIRE / September 5, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has commenced shipping its VELDONA® Pet cytoprotein supplements in Taiwan. Mr. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We have been thrilled by the positive feedback we received from our customers.

Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan

Boston, Massachusetts--(Newsfile Corp. - August 15, 2023) - Here at Horizon Insights, we see two big trends right now in healthcare - the emergence of Artificial Intelligence, or AI platforms, and the growing prevalence and acceptance of Telehealth. Ainos, Inc. (NASDAQ: AIMD), a diversified healthcare company that develops novel point-of-care testing (POCT) medical diagnostic devices and therapeutic drug candidates for treating various diseases, is developing products incorporating both these trends into one device.

Ainos, Inc - The AI Nose "Knows" What's Inside Your Body and Beyond

Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered Testing Launch of VELDONA® Pet Provides New Revenue Stream for Near-Term; Ainos Flora Remains on Horizon for 2024 SAN DIEGO, CA / ACCESSWIRE / August 11, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the second quarter ended June 30, 2023. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "The second quarter of 2023 was a transitionary period for our company.

Ainos Reports Second Quarter 2023 Financial Results

Ainos reflects upon multiple business milestones following Nasdaq listing, as it diversifies its revenues and advances its product pipeline SAN DIEGO, CA / ACCESSWIRE / August 10, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it is celebrating the one-year anniversary of its listing on the Nasdaq. To commemorate this important milestone, Nasdaq displayed a special congratulatory message on its MarketSite Tower in New York's Times Square.

Ainos Celebrates First Listing Anniversary on Nasdaq

The Collaboration Signals Era of New Innovation for AI Nose Technology for Broader Industry Adoption With Partnership, Ainos Makes Progress Towards Mission of Digitizing Smell SAN DIEGO, CA / ACCESSWIRE / August 9, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it had signed an agreement (the "Agreement") with Nisshinbo Micro Devices Inc. (NISD) and Taiwan Inabata Sangyo Co. (Inabata) to co-develop a volatile organic compound (VOC) sensing platform (the "Platform"). The Platform is intended to be used in a variety of applications including telehealth, automotive, industrial, and environmental safety.

Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption

Ainos (NASDAQ: AIMD ) stock is on the rise Friday despite a lack of news from the medical technologies company. There have been no new press releases of filings with the Securities and Exchange Commission (SEC) that explain why AIMD stock is climbing today.

Why Is Ainos (AIMD) Stock Up 82% Today?

Company ramping up marketing of VELDONA® Pet and aiming to complete clinical trials in Taiwan of its flagship AI Nose-powered POCT by the end of 2023 Ainos sees VELDONA® Pet and AI Nose-powered POCT as key drivers in transforming the company SAN DIEGO, CA / ACCESSWIRE / June 27, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, is pleased to provide a business update letter to shareholders from Ainos' Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien (Eddy) Tsai.

Ainos Issues Mid-Year Business Update Letter to Shareholders

Ainos' AI-Powered Digital Nose Technology to Transform Telehealth and Point-of-Care Testing Clinical Trials of AI Nose-powered POCT to be Completed by the End of 2023, Positioning Ainos to Capitalize on US$256 Billion STI Testing Market SAN DIEGO, CA / ACCESSWIRE / June 20, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, provides insights into its transformative AI-powered digital nose technology, AI Nose, including its design, functionality, product differentiation, and disruptive potential in the telehealth industry. Having garnered over 50 active and pending patents, Ainos' AI Nose technology embodies the essence of over 10 years of research and development in digital nose sensing, telehealth, and point-of-care testing.

Ainos Provides Insights Into Its AI Nose Technology

Five VELDONA® Pet products are now available New supplements will launch in Taiwan in July ahead of the planned international release, helping to maintain immunity for millions of pets Ainos sets its sights on entering the $137 billion US pet market SAN DIEGO, CA / ACCESSWIRE / June 14, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the launch of two new VELDONA® Pet cytoprotein supplement products. VELDONA® Pet Shiny, formulated to support pets' eye health, and VELDONA® Pet Slim, designed to help manage body weight and weight-related health issues, will be launched next month in Taiwan.

Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target

New products support pets' emotional health and allergic responses, hit market in Taiwan following successful launch of VELDONA® Pet Expanding VELDONA® Pet product line builds growth momentum toward US$20M sales target for 2024 SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the launch of two new additions to its VELDONA® Pet cytoprotein supplement product line. VELDONA® Pet Lohas, designed to support pets' emotional health and relieve stress, and VELDONA® Pet Soothing, formulated to relieve discomfort caused by allergies, will be launched in Taiwan in July.

Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target

VELDONA® Pet will hit shelves in Taiwan in June, with launches in other regions to follow Multiple new VELDONA® Pet products set to launch as Ainos enters the growing global pet care market SAN DIEGO, CA / ACCESSWIRE / May 30, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has launched its VELDONA® Pet cytoprotein health supplements. VELDONA® Pet will first be marketed in Taiwan in June, with near-term plans to expand sales and marketing in other markets.

Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales

Current CFO Celia Wu announces her retirement and transition to consulting role Sung brings nearly two decades of public company audit and compliance experience with major international accounting firms SAN DIEGO, CA / ACCESSWIRE / May 17, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the appointment of Ms. Meng-Lin (Amanda) Sung to the position of Chief Financial Officer, effective May 17, 2023.

Ainos Appoints Amanda Sung as New Chief Financial Officer

Ainos continues its strategic transition away from marketing COVID test kits and further advances commercialization of its VELDONA® and VOC POCT technologies Strategic pivot is underpinned by Ainos' diversified product pipeline SAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2023. Chun-Hsien Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "The first quarter of 2023 marks the beginning of a new chapter for Ainos.

Ainos Reports First Quarter 2023 Financial Results

Revenues increased by 3,832% year over year Debt ratio improved to 7% from 75% at year-end 2021 SAN DIEGO, CA / ACCESSWIRE / March 31, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights Revenues were US$1,038,025 in the fourth quarter of 2022, up 3,832% year over year.

Ainos Reports Fourth Quarter and Full Year 2022 Financial Results

Ainos expands market for VELDONA® low-dose interferon treatment to animal care Products expected to launch in Taiwan in Q3 2023 SAN DIEGO, CA / ACCESSWIRE / March 21, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has signed a distribution agreement (the "Agreement") with Topmed International Biotech Co., Ltd. ("Topmed"), a Taiwanese biotech company.

Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in Taiwan

Meta Materials

RLX Technology

Use these tips for buying penny stocks after hours The post Tips for Buying Penny Stocks During After Hours appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Tips for Buying Penny Stocks During After Hours

Ainos advances commercialization of its VELDONA® low-dose interferon treatment through strategic partnerships SAN DIEGO, CA / ACCESSWIRE / March 14, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has signed a Memorandum of Understanding ("MoU") with Merdury Biopharmaceutical Corp., a Taipei Exchange Emerging Stock Board listed company (TPEx: Code 6932) ("Merdury"), to jointly explore and develop a strategic business relationship. The MoU is an important component of Ainos' strategy to advance commercialization of its VELDONA® formulation.

Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients

SAN DIEGO, CA / ACCESSWIRE / March 13, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has entered into two convertible note purchase agreements, under which the Company has issued and sold two convertible promissory notes (the "Notes") in a principal amount of US$3 million to certain investors. The Notes will mature in two years following the issuance, bearing interest at the rate of 6% per annum.

News for Ainos Inc Stock (AIMD)